NewAmsterdam Pharma (NASDAQ:NAMS) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a research note published on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $52.00 price target on the stock. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at $2.24 EPS, FY2028 earnings at $3.61 EPS and FY2029 earnings at $6.74 EPS.

A number of other brokerages also recently weighed in on NAMS. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. Royal Bank Of Canada raised their target price on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an “outperform” rating in a research note on Thursday, August 7th. The Goldman Sachs Group initiated coverage on NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a “neutral” rating and a $27.00 target price for the company. Citigroup increased their price target on NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.20.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock opened at $35.00 on Monday. The firm has a market cap of $3.94 billion, a price-to-earnings ratio of -21.60 and a beta of 0.02. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $41.47. The firm has a 50 day moving average price of $28.51 and a two-hundred day moving average price of $22.60.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The company had revenue of $19.15 million during the quarter, compared to analysts’ expectations of $1.44 million. As a group, equities research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total value of $3,874,500.00. Following the completion of the sale, the chief accounting officer owned 15,000 shares of the company’s stock, valued at approximately $387,450. This trade represents a 90.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James N. Topper acquired 1,260 shares of the stock in a transaction on Monday, September 8th. The shares were acquired at an average price of $24.99 per share, for a total transaction of $31,487.40. Following the acquisition, the director owned 3,027,864 shares of the company’s stock, valued at approximately $75,666,321.36. The trade was a 0.04% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 2,391 shares of company stock valued at $58,424 and sold 226,342 shares valued at $5,748,019. Insiders own 20.84% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Mather Group LLC. bought a new stake in shares of NewAmsterdam Pharma during the third quarter worth about $28,000. Voya Investment Management LLC bought a new stake in NewAmsterdam Pharma during the 3rd quarter worth approximately $549,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in NewAmsterdam Pharma during the 3rd quarter worth approximately $30,000. China Universal Asset Management Co. Ltd. raised its stake in shares of NewAmsterdam Pharma by 2.4% in the second quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock worth $408,000 after purchasing an additional 521 shares during the last quarter. Finally, Duquesne Family Office LLC lifted its holdings in shares of NewAmsterdam Pharma by 4.0% in the second quarter. Duquesne Family Office LLC now owns 832,175 shares of the company’s stock valued at $15,071,000 after purchasing an additional 31,815 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.